

Clinical trials of rivaroxaban + aspirin

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
rivaroxaban + aspirin vs aspirin			
COMPASS (rivaroxaban + aspirin), 2017 [NCT01776424] n=27400 follow-up: 23 months	rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily) versus aspirin 100 mg once daily	Patients With Coronary or Peripheral Artery Disease	Parallel groups double-blind

More details and results :

- antithrombotics for cardiovascular prevention in patients at high risk at <http://www.trialresultscenter.org/go-Q120>
- antithrombotics for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q132>
- anticoagulant for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q481>

References

COMPASS (rivaroxaban + aspirin), 2017: